Search
for
Sort by
Research 61–90 of 67
- Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Stability and efficacy of green solvent and natural excipient-based semisolid formulations compared with conventional formulations: a review
- A Systematic Scoping Review and Conceptual Analysis of New-Onset Fibromyalgia Manifestations After Non-Hospitalized COVID-19: Empirics, Definitions, Methodologies, Pathophysiology, Mapping of Literature, and Knowledge Gaps
- Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
- Review of Promising Off-Label Use of Deucravacitinib
- Molecular Morbidity Score–Can MicroRNAs Assess the Burden of Disease?
- 51223 A novel human disease model of alopecia areata to evaluate benefit of the DHODH inhibitor farudodstat
- 90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse
- LB1777 A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata
- Image 1_Resident T cell activation leads to human hair follicle immune privilege loss ex vivo, which is prevented by the DHODH inhibitor farudodstat: relevance for alopecia areata.pdf
- ISIDLB1777 - A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
- Olorofim Effectively Eradicates Dermatophytes <i>In Vitro</i> and <i>In Vivo</i>
- Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
- Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
- 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
- 5% Minoxidil topical foam for men: Hair growth in millennials – a post hoc analysis
- “Nail loss after teriflunomide treatment: A new potential adverse event”
- Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
- Teriflunomide in multiple sclerosis: an update
- Hair Loss Associated with Teriflunomide Treatment
- Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
- HPLC-ESI-MSn characterization of phenolic compounds, terpenoid saponins, and other minor compounds in Bituminaria bituminosa
- Coffee Silverskin: A Review on Potential Cosmetic Applications
- Waterborne polyurethanes from castor oil-based polyols for next generation of environmentally-friendly hair-styling agents
- Plant Extracts in Skin Care Products
- Potential of Leucaena leucocephala and Leucaena esculenta Seeds in Human Nutrition: Composition, Techno-functional Properties, Toxicology and Pretreatment Technologies
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Network pharmacology and in vivo experimental analysis for validating the antifibrotic potential of Punica granatum leaves against skin scleroderma: the role of oxidative stress, inflammation and TGF-β1/Snail 1/p-Smad 3 signaling pathway